BRIEF-Ondas Holdings Announced Definitive Agreement To Acquire Controlling Interest In 4M Defense-February 2024-www.financetom.com

BRIEF-Ondas Holdings Announced Definitive Agreement To Acquire Controlling Interest In 4M Defense

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Ondas Holdings Announced Definitive Agreement To Acquire Controlling Interest In 4M Defense

Oct 27, 2025 7:11 AM

Oct 27 (Reuters) - Ondas Holdings Inc ( ONDS ):

* ONDAS HOLDINGS ( ONDS ): ANNOUNCED DEFINITIVE AGREEMENT TO ACQUIRE

CONTROLLING INTEREST IN 4M DEFENSE

* ONDAS HOLDINGS ( ONDS ): FOUNDING LEADERSHIP OF 4M DEFENSE WILL

REMAIN IN

PLACE

Source text:

Further company coverage:

Previous page： Precision BioSciences Q3 revenue falls sharply Next page： Scientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demand

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Precision BioSciences Q3 revenue falls sharply

Nov 3, 2025

Overview * Precision BioSciences ( DTIL ) Q3 revenue fell sharply * Net loss for Q3 widened compared to the same period last year * Company advances PBGENE-HBV and PBGENE-DMD programs with upcoming clinical milestones Outlook * Company anticipates IND filing for PBGENE-DMD by end of 2025 * Precision expects Phase 1 trial for PBGENE-DMD in 1H 2026 * Company...

Scientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demand

Nov 3, 2025

Overview * Bruker Q3 2025 revenue of $860.5 mln beats analyst expectations despite a 0.5% yoy decline * Adjusted EPS for Q3 2025 beats consensus at $0.45, despite a decline from last year * Company lowers FY2025 guidance, citing weaker demand and EPS dilution from higher share count Outlook * Bruker ( BRKR ) expects FY2025 revenue of $3.41 to...

Karyopharm Therapeutics' Q3 net loss widens

Nov 3, 2025

Overview * Karyopharm Q3 total revenue rises to $44 mln, driven by XPOVIO sales growth * Net loss for Q3 2025 was $33.1 mln, slightly higher than last year * Company reaffirms full-year 2025 revenue guidance of $140 mln to $155 mln Outlook * Karyopharm reaffirms 2025 total revenue guidance of $140 mln to $155 mln * Company expects 2025...

TG Therapeutics Q3 revenue up on strong demand, raises 2025 forecast

Nov 3, 2025

Overview * TG Therapeutics Q3 2025 revenue was $161.7 mln, driven by BRIUMVI sales * Company raises 2025 global revenue target to $600 mln, BRIUMVI U.S. target to $585 mln * Completed $100 mln share repurchase, authorized additional $100 mln program Outlook * TG Therapeutics ( TGTX ) raises 2025 global revenue target to $600 mln * Company increases 2025...